Authors :
Presenting Author: Pavel Vlasov, MD – Department of Neurology, Scientific Research Institute of Clinical Medicine named after N.A. Semashko, Russian University of Medicine; Moscow, Russia
Irina Zhidkova, MD – Department of Neurology, Scientific Research Institute of Clinical Medicine named after N.A. Semashko, Russian University of Medicine; Moscow, Russia
Vladimir Karlov, MD – Department of Neurology, Scientific Research Institute of Clinical Medicine named after N.A. Semashko, Russian University of Medicine; Moscow, Russia
Natalia Filatova, PhD – Department of Neurology, Scientific Research Institute of Clinical Medicine named after N.A. Semashko, Russian University of Medicine; Moscow, Russia
Tatiana Danilova, MD – Department of Neurology, Kazan State Medical University, Kazan, Russia
Rationale:
To evaluate the effect of PER on sleep quality, daytime sleepiness, anxiety, and depression when used as an additional anti-seizure medication (ASM) in the treatment of epilepsy in adults.
Methods:
The study included 106 patients with focal (n=96) and other forms (n=10) of epilepsy aged 18 to 73 years. PER was prescribed as an additional ASM when previous therapy was partially effective, regardless of the presence/absence of complaints of insomnia. Study design: multicenter, observational, prospective, lasting for 12 months. At baseline and after 1, 3, 6 and 12 months of PER use, the dynamics (Wilcoxon), sleep quality (Pittsburg), daytime sleepiness (Epwort), and anxiety/depression level (HADS) were analyzed.Results: By 12 months of observation, the retention rate was 84.9%. PER was discontinued in only 15.1% of patients, of which 5.7% were due to adverse events (AE). The most common AE was dizziness; no new, previously unreported AEs were reported. The use of PER after 1 month of therapy significantly reduced daytime sleepiness (P< 0.037) and improved sleep quality (P< 0.001). The use of PER as part of complex therapy led to improvement in the initially subclinical anxiety level (P< 0.001) changing to normal level. The depression index was initially normal, but also further decreased (P< 0.001).